Results 131 to 140 of about 564,320 (308)

Drug utilization studies in Turkiye: A systematic review

Northern Clinics of Istanbul
Drug utilization studies (DUS) provide a framework for drug utilization at the national or targeted population level and important information on unmet medical needs, particularly in assessing the rationality of drug use. We aimed to systematically review DUS conducted in Turkiye.We examined 162 DUS with an accessible full-text, published as "research ...
Akıcı, Ahmet, Havyarimana, Dieudonné, Direnç, Ertan, Aydın, Volkan   +3 more
openaire   +3 more sources

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Analysis of the activities of the clinical pharmacy service in the use of vancomycin in a public hospital in Belo Horizonte

Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
Objective: To characterize the population in vancomycin use, and analyze the parameters of indication, effectiveness and safety used by clinical pharmacists in the drug utilization review.
Ana Carolina AUGUSTO, Amanda Fonseca MEDEIROS, Maria Auxiliadora MARTINS, Clara Lemos LEITÃO, Mário César BRANDÃO, Elaine Ferreira DIAS, Caryne Margotto BERTOLLO   +6 more
doaj   +1 more source

The Regulatory Component of Health Care Reform [PDF]

, 2008
Explains the rationales and goals of regulatory intervention. Assesses the likelihood that proposed changes to regulations will be implemented as a component of healthcare reform or that they will help control costs and improve ...
Roger G. Noll
core  

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Employer-Sponsored Health Insurance: Down, But Not Out [PDF]

, 2011
Presents findings from twelve metropolitan areas about employers' efforts to control employee healthcare costs in response to the recession and national healthcare reform by firm size.
Divya R. Samuel, Ha T. Tu, Jon B. Christianson   +2 more
core  

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Drug utilization studies from secondary databases in latent tuberculosis: a scoping review protocol

Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
This article introduces a protocol for a scoping review that aims to map and synthesize Drug utilization studies from secondary databases in latent tuberculosis The protocol is intended to document the processes involved in the methodological planning ...
Luiz Villarinho MENDES, Juliana Villar GUIMARÃES, Rondineli Mendes SILVA, Claudia Garcia OSORIO-DE-CASTRO   +3 more
doaj   +1 more source